Safety and immunogenicity of BNT162b2 vaccine in children with acute leukaemia: results and perspectives of an open-label, two-centre, phase 1/2 trial with dose finding study
Vaccination of children with acute leukaemia with adult doses (30 μg) of BNT162b2 is well tolerated and results in significant T-cell response children with AL, even during chemotherapy. As doses of 10 μg is currently recommended for children, these results support the value of increasing vaccine doses in immunocompromised patients.
Authors
- Audrey Guilmatre
- Marion Strullu (ORCID: https://orcid.org/0000-0002-9229-0150)
- Chaima Mrad (ORCID: https://orcid.org/0000-0003-4442-7316)
- Lucienne Chatenoud (ORCID: https://orcid.org/0000-0002-1328-2786)
- Maxime Ferreboeuf
- Florentia KAGUELIDOU
- Fanny Alby-Laurent (ORCID: https://orcid.org/0000-0002-6195-5180)
- Amani Ouedrani
- Laurence Morand-Joubert (ORCID: https://orcid.org/0009-0002-7269-2328)
- Odile Launay
- Sylvie Chevret
- Pierre Jateau
- Anouk Walter-Petrich
- Arnaud Petit
- Anne-France Ray-Lunven
Institutions
- Hôpital Necker-Enfants Malades (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Institut Necker Enfants Malades (FR)
- Hôpital Armand-Trousseau (FR)
- Hôpital Cochin (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Fernand-Widal (FR)
- Hôpital Robert-Debré (FR)
- Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR)
- Institut Cochin (FR)
- Hôpital Saint-Louis (FR)
Publication Details
- Journal
- Vaccine
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1016/j.vaccine.2025.128130
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00